Published on 8 Jun 2023 on Simply Wall St. via Yahoo Finance
There wouldn't be many who think Enzo Biochem, Inc.'s (NYSE:ENZ) price-to-sales (or "P/S") ratio of 1.3x is worth a mention when the median P/S for the Healthcare industry in the United States is very similar. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
View our latest analysis for Enzo Biochem
ps-multiple-vs-industry